Treatment

177Lu HTK03170 clinical trials

1 indexed studies · 1 currently recruiting

Enrolling by invitationPHASE1, PHASE2
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
This study is for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It tests a new radioactive drug called 177Lu-HTK03170 to find the safest dose and see if it can shrink the cancer.
For: Metastatic Castration-resistant Prostate Cancer · Prostate Cancer Metastatic · Castrate Resistant Prostate Cancer
Canada